The Importance of Mammography as an Early Screening Mechanism for Breast Cancer in Patients with a Family History: A Review
DOI:
https://doi.org/10.36557/2674-8169.2024v6n9p3084-3093Keywords:
Mamografia, Prevenção do Câncer, Neoplasia da Mama, GenéticaAbstract
Introduction: Breast carcinoma is one of the most prevalent neoplasms among women worldwide. Its clinical manifestations can range from palpable nodules or masses to changes in the skin of the breast, such as retraction or change in nipple color. In this context, mammography is considered the gold standard exam for the early diagnosis of neoplasms, providing more effective treatment with lower risk to the patient. Objective: This review aims to present and discuss, in a concise manner, the most recent and relevant findings on the impact of mammography as a mechanism for early screening of breast cancer in patients with a family history. Methods: Searches were performed in the PubMed and Lilacs databases using selected inclusion and exclusion descriptors. Each selected article was read in full by at least two researchers. Results: Based on critical selection of the research, 14 articles were selected for this review. Data from 428,560 women indicated that cancer detection rates were lower in women under 40 years of age. Interviews with physicians revealed that risk assessment is influenced by knowledge, beliefs, and prior experiences, creating barriers to appropriate referrals for genetic counseling and screening programs. Conclusion: In summary, mammography plays a crucial role in the early detection of breast cancer, especially in women in their 40s. In this context, women with a hereditary history of breast cancer and/or alterations in the BRCA1, BRCA2, and CHEK2 genes should undergo mammograms more frequently, ideally once a year. However, further studies are needed to accurately determine an effective treatment plan.
Downloads
References
National Cancer Institute. Annual Report to the Nation on the Status of Cancer, 2021. Bethesda, MD: National Cancer Institute; 2021.
American Cancer Society. Cancer Facts & Figures 2020. Atlanta: American Cancer Society; 2020.
Ministério da Saúde (BR). Brasília (DF): Ministério da Saúde; 2004.
Nadler MB, Corrado AM, Desveaux L, Neil-Sztramko SE, Wilson BE, Desnoyers A, et al. Determinants of guideline-concordant breast cancer screening by family physicians for women aged 40-49 years: a qualitative analysis. CMAJ Open. 2022 Oct 18;10(4):E900-E910. doi: 10.9778/cmajo.2021026634. PMID: 36257683; PMCID: PMC9616605561.
Okazaki M, Bando H, Tohno E, Kujiraoka Y, Iguchi-Manaka A, Ichioka E, et al. Investigation of the significance of population-based breast cancer screening among women aged under 40 years. Breast Cancer. 2021 Jan;28(1):75-81. doi: 10.1007/s12282-020-01131-x. Epub 2020 Jul 8. PMID: 32643018.
Guo F, Adekanmbi V, Hsu CD, Berenson AB, Kuo YF, Shih YT. Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention. JAMA Netw Open. 2024 Feb 5;7(2):e2356078.
Padrik P, Puustusmaa M, Tõnisson N, Kolk B, Saar R, Padrik A, et al. Implementation of Risk-Stratified Breast Cancer Prevention With a Polygenic Risk Score Test in Clinical Practice. Breast Cancer (Auckl). 2023 Oct 12;17:11782234231205700. doi: 10.1177/1178223423120570023. PMCID: PMC105716984. PMID: 378422305.
Guo B, Knerr S, Kauffman TL, Mittendorf KF, Keast E, Gilmore MJ, et al. Risk management actions following genetic testing in the Cancer Health Assessments Reaching Many (CHARM) Study: A prospective cohort study. Cancer Med. 2023 Sep;12(18):19112-25. doi: 10.1002/cam4.648523. Epub 2023 Aug 30. PMID: 37644850; PMCID: PMC1055787856.
Henderson V, Madrigal JM, Kendall LC, Parekh P, Newsome J, Chukwudozie IB, et al. A pilot. BMC Health Serv Res. 2022 Jun 25;22(1):826. doi: 10.1186/s12913-022-08193-x. PMCID: PMC9233847. PMID: 35752812.
Holowko N, et al. Heritability of Mammographic Breast Density, Density Change, Microcalcifications, and Masses. Cancer Res. 2020 Apr 1;80(7):1590-1600. doi: 10.1158/0008-5472.CAN-19-2895. PMID: 32241951.
Kim G, Bahl M. Assessing Risk of Breast Cancer: A Review of Risk Prediction Models. J Breast Imaging. 2021;3(2):144-155. doi: 10.1093/jbi/wbab001. PMCID: PMC7980704. PMID: 33778488.
Schonberg MA, Davis RB, Karamourtopoulos MC, Pinheiro A, Sternberg SB, Jacobson AR, et al. A Pre-Test–Post-Test Trial of a Breast Cancer Risk Report for Women in Their 40s. Am J Prev Med. 2020 Sep;59(3):343-54. doi: 10.1016/j.amepre.2020.04.014.
Kleiblová P, Stolařová L, Křížová K, Lhota F, Hojný J, Zemánková P, et al. Germline CHEK2 gene mutations in hereditary breast cancer predisposition - mutation types and their biological and clinical relevance. Klin Onkol. 2019 Summer;32(Suppl2):36-50. doi: 10.14735/amko2019S36.
Evans DG, Harkness EF, Brentnall AR, van Veen EM, Astley SM, Byers H, et al. Risk stratification models better predict breast cancer pathology and stage. Breast Cancer Res Treat. 2019 Jul;176(1):141-148. doi: 10.1007/s10549-019-05210-2. Epub 2019 Apr 24. PMID: 30941651; PMCID: PMC6548748.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Rhuan Nantes Fontoura Teofilo, Carolina Dossena, Camilla Rodrigues Pereira da Silva, Maria Júlia Dacas Dacheux, Bruna Vitória Nichio Biazi, Lanna Gabriela Rodrigues Frabetti, Yuri Locatelli Stunitz, Milena Azeredo de Andrade Daga, Lucas Mateus Rodrigues de Freitas, Maria Carolina Casagrande, Letícia Satim

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.



